Research Compound
GLP-3R
GLP-3R is a synthetic 39-amino acid acylated peptide classified as a triple receptor agonist (GLP-1, GIP, and glucagon receptors), available as a lyophilized powder for laboratory research.
Select Size
15mg
SKU: RT15
Batch: 202609-01-RT
$86.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/18/2026
Volume Discounts
Qty: 1 - 4$86.99 each
Qty: 5 - 9$78.29 each(save $8.70)
Qty: 10+$69.59 each(save $17.40)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Product Details
GLP-3R is a synthetic 39-amino acid peptide classified as a triple agonist targeting GLP-1, GIP, and glucagon receptors. Features fatty acid modification (acylation) for albumin binding and extended half-life.
Triple-receptor binding profile distinguishes it from single-agonist and dual-agonist peptides. Provided as lyophilized powder requiring reconstitution with bacteriostatic water. Store at -20°C protected from light.
Disclaimer: For laboratory and research purposes only. Not intended for human consumption.
Frequently Asked Questions About GLP-3R
Answers summarize published research and are provided for laboratory research purposes only.
GLP-3R is a synthetic 39-amino acid acylated peptide classified as a triple agonist of the GLP-1, GIP, and glucagon receptors. It carries a fatty acid modification that binds albumin. Research studies have examined GLP-3R in models of body weight regulation, glucose control, and liver fat, and it is supplied by Biotech Compounds as a lyophilized powder for laboratory research.
In research studies, GLP-3R has been shown to activate three receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Researchers have reported that GLP-1 and GIP receptor activation are linked to glucose-dependent insulin release and reduced food intake, while glucagon receptor activation has been associated with increased energy expenditure and liver fat mobilization in animal models. GLP-3R is designed so that these three signals act together.
The glucagon receptor component sets GLP-3R apart from single and dual incretin agonists. Published research suggests that glucagon receptor signaling raises energy expenditure and promotes fat oxidation in the liver. On its own that signal would also raise blood glucose, but in research studies the paired GLP-1 and GIP receptor activity of GLP-3R has been reported to offset that effect. Researchers use GLP-3R to study whether this balanced triple signal produces larger metabolic changes.
The primary research area for GLP-3R is body weight regulation. In rodent models, researchers have reported that GLP-3R produces greater reductions in body weight and fat mass than single GLP-1 receptor agonists tested under similar conditions. Clinical trials of this triple agonist, including phase 2 studies, have reported body weight and glycemic outcomes. GLP-3R is the peptide researchers choose when the study question is the combined effect of all three receptors.
GLP-3R has been examined in several secondary research areas. In research studies, triple agonists of this type have been evaluated for effects on liver fat content and markers of fatty liver in both animal models and clinical trials. Researchers have also reported data on lipid profiles, blood pressure, and glucose control. In animal models, GLP-3R has been studied for changes in energy expenditure and substrate use tied to its glucagon receptor activity.
GLP-3R is an investigational peptide. Research on this triple agonist includes in vitro receptor assays, rodent studies, and an active clinical trial program that has published phase 2 results in the metabolic field, with later phase trials ongoing. Unlike GLP-1S and GLP-2T, peptides of the GLP-3R structure have not completed a full approval pathway anywhere. The GLP-3R sold by Biotech Compounds is a research-grade material for laboratory study.
The three house GLP peptides differ by receptor count. GLP-1S is a single GLP-1 receptor agonist. GLP-2T is a dual agonist of the GIP and GLP-1 receptors. GLP-3R is a triple agonist that adds the glucagon receptor. In research studies, each additional receptor has been associated with a distinct metabolic profile, and researchers have reported the largest body weight effects in animal models with the triple agonist GLP-3R.
GLP-3R is a single triple-agonist peptide. Cagri-GLP3R is a research blend that pairs GLP-3R with Cagrilintide, a long-acting amylin analog. In research studies, amylin receptor agonists have been reported to reduce food intake through a pathway separate from the GLP-1, GIP, and glucagon receptors. Researchers choose GLP-3R alone to study the triple agonist by itself and choose Cagri-GLP3R when the study adds amylin signaling.
GLP-3R is supplied as a lyophilized powder that requires reconstitution with bacteriostatic water. The diluent is added slowly along the inside wall of the vial, and the vial is swirled gently until the GLP-3R powder dissolves. The vial must never be shaken. GLP-3R is an acylated peptide, so a little extra swirling time may be needed before the solution turns fully clear.
Lyophilized GLP-3R should be stored frozen at minus 20 C and protected from light. After reconstitution, GLP-3R should be kept refrigerated at 2 to 8 C, shielded from light, and used within the timeframe set by the research protocol. Repeated freeze and thaw cycles should be avoided. Research studies have reported that the albumin-binding fatty acid chain of GLP-3R extends its half-life in biological systems, but cold storage of the vial is still required.
GLP-3R has a molecular weight of 4,731.33 Da and a molecular formula of C221H342N46O68. It is a 39-amino acid acylated peptide. Biotech Compounds supplies GLP-3R as a lyophilized powder with a purity of 99 percent or higher, confirmed by third-party testing. The Certificate of Analysis for each lot of GLP-3R is available on the product page so researchers can verify identity and purity before ordering.
No. GLP-3R is sold strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. GLP-3R from Biotech Compounds is not a drug or a dietary supplement, it is not a substitute for any prescription product, and it is not for human or animal consumption.
You May Also Like
